Jeremy Schafer, senior VP at Precision for Value, answered questions from Med Ad News as to what manufacturers can do if price disclosures in ads become a reality.

Express Scripts Holding Co. built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now the pharmacy benefit manager is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Publicis Health acquired Payer Sciences, an innovative, data-and-analytics-driven health marketing agency focused on helping biopharmaceutical manufacturers navigate the dynamic U.S. reimbursement environment.

Publicis Health announced the acquisition of Payer Sciences, an innovative data-and-analytics-driven health marketing agency.

As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.

The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.

ZS oncology experts Christina Corridon and Pavan Anne discuss their recent survey of physicians, payers, and pharmacy managers regarding attitudes toward biosimilars

Most health plans are covering at least one of the two biosimilar products currently on the market, according to new research by the strategic advisory company Avalere.

Four in five oncologists have tried Zarxio/Granix, according to a new survey by ZS Associates. Of those, 48 percent prescribe the reference biologic more than the biosimilar, 43 percent prescribe the biosimilar more, and 8 percent have equal prescriptions for the reference biologic and the biosimilar.

The National Pharmaceutical Council will host a webinar, “Same Condition, Different Costs: Should Patients Pay Different Amounts?” to discuss the practical realities of different cost-sharing models for prescription drugs.